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Abstract
The avb6 integrin is up-regulated in cancer and wound healing but it is not generally expressed in healthy adult tissue. There
is increasing evidence that it has a role in cancer progression and will be a useful target for antibody-directed cancer
therapies. We report a novel recombinant diabody antibody fragment that targets specifically avb6 and blocks its function.
The diabody was engineered with a C-terminal hexahistidine tag (His tag), expressed in Pichia pastoris and purified by IMAC.
Surface plasmon resonance (SPR) analysis of the purified diabody showed affinity in the nanomolar range. Pre-treatment of
avb6-expressing cells with the diabody resulted in a reduction of cell migration and adhesion to LAP, demonstrating
biological function-blocking activity. After radio-labeling, using the His-tag for site-specific attachment of 99mTc, the diabody
retained affinity and targeted specifically to avb6-expressing tumors in mice bearing isogenic avb6 +/2 xenografts.
Furthermore, the diabody was specifically internalized into avb6-expressing cells, indicating warhead targeting potential.
Our results indicate that the new avb6 diabody has a range of potential applications in imaging, function blocking or
targeted delivery/internalization of therapeutic agents.
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Introduction
The avb6 integrin is an epithelial restricted trans-membrane
protein that has emerged as a promising target for antibody-
directed therapies. It is up-regulated in many tumor types
including pancreatic ductal adenocarcinoma, head and neck
squamous cell carcinoma, ovarian cancer, colon cancer, cholan-
giocarcinoma and cervical cancer [1,2,3,4,5]. During embryogen-
esis and wound healing avb6 promotes binding to extracellular
matrix proteins (fibronectin, vitronectin and tenascin) facilitating
cell migration [6] and activates TGFb1 via binding to the latency
associated peptide (LAP) of the TGFb complex [7]. In cancer,
avb6 has been shown to modulate invasion, inhibit apoptosis and
regulate expression of matrix metalloproteases (MMPs) [8].
Importantly for a cancer target, avb6 is only found at very low
levels in normal tissue; its expression has been reported to regulate
wound healing [6] and activation of TGFb1 in response to injury
and inflammation in the lungs [9].
The various roles of avb6 in cancer have not yet been fully
elucidated, although it has been shown to be a contributing factor
in tumor progression [4,10] and has been associated with
enhanced tumorigenic properties in colon carcinoma facilitating
liver metastasis [4,11], and reducing survival times in gastric
carcinoma [10]. Expression of avb6 has been reported during
epithelial-mesenchymal transition (EMT) and it is thought to have
a role in sustaining the EMT process [12,13]. Interestingly, high
levels of avb6 are found in the context of K-Ras dependency in
lung and pancreatic cancer cell lines [14]. Depletion of the ITGB6
gene had a clear growth inhibitory effect on these cells [15],
indicating that avb6 may be a tractable target in K-Ras mutant
cancers. Targeting this integrin has shown tumor growth
inhibition in vivo due to blockade of avb6-dependent activation of
the TGFb pathway [16].
Antibodies reactive specifically with avb6 could have diagnostic
and therapeutic utility, particularly if they have function blocking
activity. Towards this, we previously engineered murine and
humanized single chain Fv antibody fragments (scFvs) reactive
with avb6 [17]. The unique avb6 specificity was gained by an
insertion into the CDR3 loop of the variable heavy-chain (VH)
domain of an existing scFv scaffold. Here we describe the
development of an anti-avb6 scFv into a stable in vivo targeting
agent in diabody format. Diabodies are non-covalently associated
bivalent molecules, created from scFvs by shortening the
polypeptide linker between the VH and VL domains [18]. Their
bivalent nature is advantageous for targeting [19,20,21] and they
provide a flexible platform for development of targeted therapeu-
tics, particularly since their pharmacokinetics are readily modified
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by attachment of polyethylene glycol [22]. We show that the anti-
avb6 diabody blocks avb6-mediated biological functions. More-
over, the 99mTc-labeled diabody targeted specifically to avb6+ve
tumors in vivo within 2 hours of administration.
Materials and Methods
Cell lines
A375Pb6 is a avb6-positive human cell line, generated through
retroviral transduction of the melanoma cell line A375P with
human b6 cDNA and a puromycin-resistance gene as described
previously [23]. The control cell line, A375Ppuro was transduced
with the puromycin-resistance gene alone [23]. Both cell lines
express several other RGD-binding integrins at equivalent levels,
namely a5b1, avb3, avb5, avb8 [17]. Capan-1 (avb6-positive human
pancreatic cell line) was obtained from ATCC (HTB-79). All cell
lines were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) (PAA Laboratories, UK) supplemented with 2 mM L-
glutamine (PAA Laboratories, UK) and 10% foetal calf serum
(Labtech International, Ringmer, UK).
Production of B6.3 and shMFE23 diabody proteins
The diabody was generated from the B6.3 scFv vH and vL
domains [17] by synthesizing the scFv gene with a G4S linker. The
synthesized gene was obtained from Genescript (Piscataway, NJ,
USA) and cloned into the pPICZaBHis vector (Invitrogen) as
described previously [17]. The resulting plasmid was linearized
with PmeI, transformed into electrocompetent P. pastoris X33 cells
(Invitrogen) and transformants grown on YPDS and Zeocin
(100 mg/ml; Invitrogen) plates. Positive clones were selected and
screened for methanol-induced protein expression according to
the manufacturer’s recommendations. Clones with the highest
B6.3 diabody expression were used for protein production by
fermentation with initial purification using expanded-bed adsorp-
tion IMAC as previously described [24,25]. The B6.3 diabody was
harvested 4 h post induction of protein expression. Final
purification was performed by size-exclusion chromatography on
a Superdex 75 (GE Healthcare) column (500-ml bed volume)
equilibrated with phosphate-buffered saline (PBS), pH 7.4. For
99mTc labeling experiments the diabody was further concentrated
Figure 1. Production of B6.3 diabody and analysis of its specific interaction with avb6. A) Size-exclusion chromatographic profile
(Superdex 75, 125 ml) of B6.3 diabody after fermentation, expanded-bed adsorption IMAC, Superdex 75 (500 ml), 1 ml Ni2+-charged Hi-Trap IMAC,
freezing and de-frosting. B6.3 diabody eluted from the column as a dimer that separated in monomeric form under reducing conditions by SDS-
PAGE, consistent with non-covalent association of monomers in a diabody structure. B) Sensogram of real-time binding and dissociation of B6.3
diabody to avb6. B6.3 diabody was immobilized on a BIAcore CM5 sensor chip and avb6 protein was flown across at 400, 200, 100, 50, 25, 12.5, 6.25
and 3.125 nM. The affinity constant (KD) for the interaction was 2.861029 M, with on-rate of 8,10767.3 M21s21 and off-rate of
2.36102561.461027 s21. C) Flow cytometry analysis of B6.3 diabody binding to avb6-expressing A375Pb6 cells in a concentration-dependent
manner (a) but not to A375Ppuro cells (b), which do not express this integrin. Cells were incubated with B6.3 diabody, at the indicated concentrations
and binding was detected with mouse anti-tetra-histidine IgG followed by R-PE-labeled goat anti-mouse IgG. B6.3 diabody was not added to
omission control (shown in solid grey). D) Inhibition of B6.3 diabody binding after incubation with the anti-avb6 antibody 10D5 shown by flow
cytometry. Cells were incubated with 100 ng B6.3 diabody with or without prior incubation with 10D5 at the indicated concentrations. Binding of
B6.3 diabody was detected with rabbit anti-hexahistidine IgG followed by R-PE-labeled goat anti-rabbit IgG. In the omission control experiment
(shown in solid grey) cells were not incubated with B6.3 diabody and 10D5.
doi:10.1371/journal.pone.0073260.g001
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to 7.3 mg/ml by application to a 1ml Ni2+-charged HiTrap IMAC
SP FF column (GE Healthcare) according to the manufacturer’s
instructions. Purified protein was analyzed by SDS-PAGE using
Tris-glycine gels (16%; Invitrogen) and stained with Coomassie
brilliant blue R250 (Sigma). The shMFE23 diabody was produced
following the same protocol as for B6.3 diabody production, using
the shMFE23 scFv [26] vH and vL domains as template. The
purified protein gave a single peak by size exclusion chromatog-
raphy (data not shown) indistinguishable from that obtained with
the B6.3 diabody.
Affinity of avb6 binding to B6.3 diabody by Surface
Plasmon Resonance
Affinity of purified B6.3 diabody for avb6 was measured by
surface plasmon resonance (SPR) using a Biacore T100. The
diabody was immobilized on a Research Grade CM5 chip using
an amine coupling kit (BIAcore, GE Healthcare). Recombinant
avb6 protein (R&D Systems) was flown over the immobilized B6.3
diabody in HBS-P buffer (10 mM HEPES, 150 mM NaCl, 0.05%
v/v Surfactant P20, pH 7.4, with addition of 2 mM Ca2+ and
2 mM Mg2+ ions) at 30 mL/min at 25uC. Association and
dissociation phases occurred over 300 s. Kinetics of binding was
calculated from data at 400 nM, 200 nM, 100 nM, 50 nM,
25 nM, 12.5 nM, 6.25 nM and 3.125 nM using the BIAevalua-
tion program. The surface was regenerated with 10 mM Glycine-
HCl, pH 2.5. The affinity constant (KD) was obtained by
simultaneously fitting the association and dissociation phases of
the sensogram from the analyte concentration series using the 1:1
Langmuir model (BIAevaluate software).
Flow cytometric analysis of B6.3 diabody binding to avb6-
expressing cells
A375Pb6 and A375Ppuro cells were trypsinized, re-suspended
in DMEM supplemented with 0.1% (v/v) BSA and 0.1% (w/v)
sodium azide (DMEM0.1/0.1) to approximately 56106 cells/ml
and incubated with various concentrations of B6.3 diabody.
Bound diabody was detected with mouse Tetra-His antibody
(1 mg/ 100 ml, Qiagen) and R-PE-conjugated goat anti-mouse IgG
Figure 2. Treatment of avb6-expressing cells with B6.3 diabody resulted in diabody internalization and blockade of integrin
functions. A) Localization of B6.3 diabody in A375Pb6 cells by confocal microscopy. B6.3 diabody detection showed membrane pattern of staining
at 4uC and internalized when cells were incubated at 37uC for 30 min, 1 h and 3 h. B6.3 diabody was detected using rabbit anti-human IgG followed
by Alexa Fluor 546H-labeled goat anti-rabbit IgG (red). Cells were also counterstained with Hoechst 33245 (blue). B) Treatment of avb6-expressing
cells blocked adhesion to LAP-coated plates (A375Pb6 and Capan-1 cells) and/or fibronectin-coated plates (Capan-1 cells). Cells were incubated with
B6.3 or shMFE23 diabody at 4uC for 1 h and allowed to attach to coated plates for 1 h at 37uC. Treatment with the anti-CEA shMFE23 diabody had no
effect on the cell lines used. C) B6.3 diabody treatment inhibited migration towards LAP and fibronectin. As observed in adhesion assays, the diabody
inhibited migration of A375Pb6 cells to LAP and migration of Capan-1 cells to fibronectin and LAP, while targeting CEA had no effect on the cells
tested.
doi:10.1371/journal.pone.0073260.g002
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(BD Pharmingen, 1 mg/100ml). Detection antibodies were incu-
bated in DMEM0.1/0.1 for 45 min at 4uC; all incubations were
followed by washing with DMEM0.1/0.1. Cells were fixed with
IntraStain kit (DakoCytomation, Glostrup, Denmark) and ana-
lyzed by flow cytometry using a CyAn ADP High-Performance
Flow Cytometer (Becton Dickinson). For binding inhibition
studies, A375Pb6 cells were incubated with mouse anti-avb6
(10D5, Chemicon International) at various concentrations for
15vmin followed by incubation with 100 ng (18.04 nM) of
diabody for 30 min. After washing, bound diabody was detected
with rabbit anti-hexahistidine IgG (GenScript) at 1 mg/100 ml,
followed by R-PE-conjugated goat anti-rabbit IgG (1 mg/100 ml,
Invitrogen). All incubation and washing steps were in DMEM0.1/
0.1 at 4uC. Cells were fixed and analysed as described above.
99mTc labeling of B6.3 diabody
Sodium [99mTc] pertechnetate was obtained from a
99Mo/99mTc generator (GE Healthcare, Amersham UK) and
converted to [99mTc(CO)3(H2O)3]
+using an IsoLinkTM kit (gener-
ously provided by Covidien, Petten, The Netherlands) according
to the manufacturer’s instructions. B6.3 diabody was labeled at the
C-terminal hexahistidine tag with 99mTc by incubating with
750MBq of [99mTc(CO)3(H2O)3]
+ in a total volume of 574 ml at
37uC for 2 h. The labeled protein was separated from the non-
incorporated radionuclide by desalting (NAP-10 column, GE
Healthcare). Integrity of the radio-labeled protein as a dimer was
verified by size-exclusion HPLC on a Biosep-SEC-S 2000 column
eluted with 0.1 M phosphate buffer pH 7 at a flow rate of 0.5 ml/
min.
Cell Saturation Binding Assay
The immunoreactivity and affinity of 99mTc-labeled B6.3
diabody to avb6 was analyzed by a saturation-binding assay using
A375Pb6 cells. Six duplicate test samples containing increasing
amounts of 99mTc-labeled B6.3 diabody and approximately
6.56105 A375Pb6 cells per experiment were incubated in a total
volume of 1ml of DMEM with 0.1% (v/v) BSA (DMEM0.1) at
4uC for 3 h. Supernatant was removed by centrifugation and cells
were washed once with DMEM0.1. An identical series of tubes
were prepared in which non-specific binding was determined by
addition of 25 mg unlabeled diabody to each tube. Non-specific
binding was subtracted from total binding to obtain specific
binding. Affinity constant (KD) and maximal number of avb6
binding sites (Bmax) were determined by non-linear regression
analysis using Graphpad prism software.
Immunofluorescence microscopy of internalization of
B6.3 diabody into avb6-expressing cells
A375Pb6 cells were seeded on to glass cover slips at 26105
cells/well and incubated for 48 h at 37uC. Cells were then washed
with DMEM0.1, incubated with 5 mg/ml of B6.3 diabody in
1%BSA/DMEM (DMEM1) for 1 h at 4uC and subsequently
washed and incubated in 10% (v/v) FBS/DMEM at 37uC for
various time points. After incubation, cells were washed twice with
Tris-Cl, pH 7.5, containing 2 mM Ca2+ and 1 mM Mg2+ (Tris/
M), followed by fixation in 4% paraformaldehyde/Tris/M for
20 min on ice. After washing with PBS, cells were incubated with
10 mM ammonium chloride/PBS for 10 min at room tempera-
ture and permeabilized with ice-cold methanol. Finally, cells were
blocked with 1% (w/v) BSA/PBS for 30 min at room temperature
and stained with 1 mg/ml of rabbit anti-human IgG (Jackson
Immuno Research, Suffolk, UK) in 1% (w/v) BSA/PBS followed
by Alexa Fluor 546H-labeled goat anti-rabbit IgG (1:500)
(Invitrogen), containing Hoechst trihydrochloride (1:5000) (Invi-
trogen) in 1% (w/v) BSA/PBS, each for 1 h at 4uC. Cover slips
were mounted on slides using ProLong Gold antifade (Invitrogen)
and examined using Perkin Elmer Spinning Disc Confocal
microscope and VolocityTM Visualisation Software.
Adhesion assays
Ninety-six-well plates were coated with 100 ml of fibronectin
(R&D Systems) at 25 mg/ml or LAP (R&D Systems) at 0.5 mg/ml
for 1 h at 37uC. After coating, plates were washed with PBS and
blocked with 1%BSA/PBS at 37uC for 1 h. For blocking
experiments, cells were treated with 50 mg/ml B6.3 diabody for
1 h at 4uC in DMEM0.1 and seeded at 56104 cells/well. After
incubation at 37uC for 1 h, plates were extensively washed with
PBS to remove non-attached cells and 100 ml of a dilution 1:10 of
Figure 3. B6.3 diabody inhibited LAP-mediated Smad2/3
translocation to the nucleus in Capan-1 cells. Cells were
incubated at 4uC in the presence of B6.3 diabody and then treated
with LAP or TGFb1 (30 min, 37uC); Smad2/3 localization was assessed by
confocal microscopy (40X) using rabbit anti-Smad2/3 followed by Alexa
Fluor 488H-labeled goat anti-rabbit IgG (green); smad2/3 was found in
the cytoplasm of starved Capan-1 cells (a) and after treatment with B6.3
diabody (c). Smad2/3 was present in the nuclei in response to treatment
with latent TGFb1 (b), a translocation that was inhibited by pre-
treatment B6.3 diabody (d). TGFb1 was used as a positive control (e.f).
doi:10.1371/journal.pone.0073260.g003
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Prestoblue (Invitrogen) was added to each well. Fluorescence
signal was measured after incubation at 37uC for 4 h using a
Multimode Varioskan plate reader (Thermo Scientific). Results
were expressed as percentage of attachment relative to untreated
cells with statistical significance analyzed by Student’s unpaired t-
test.
Migration assays
Cell migration was analysed using Transwell assays (Corning,
NY, USA) with polycarbonate filters (8 mm pore size). Membrane
undersurface was coated with fibronectin (R&D Systems) at
25 mg/ml or LAP (R&D Systems) at 0.5 mg/ml for 1h at 37uC and
blocked with DMEM0.1 for 1 h at 37uC. Cells were treated as
described for adhesion assays and seeded in the upper chamber at
16105 cells/chamber in 100 ml. The lower chamber was filled
with 600 ml DMEM0.1. Plates were then incubated for 20 h at
37uC and cells in the upper chamber were carefully removed using
a cotton swap. Migrated cells were fixed with 4% paraformalde-
hyde, stained with Hoechst trihydrochloride (1:5000) (Invitrogen)
for 10 min and counted using a Zeiss AxioImager A1 fluorescence
microscope with AxioVision software. Results were expressed as
percentage of migrated compared to untreated cells with statistical
significance analyzed by Student’s unpaired t-test.
Immunocytofluorescence for Smad2/3 localization
Capan-1 cells were seeded in cover slips in 10% (v/v) FBS/
DMEM and allowed to grow to 70% confluency. Cells were then
washed twice in PBS, starved for 24 h in serum-free DMEM and
treated with 50 mg/ml B6.3 diabody for 1 h at 4uC in DMEM0.1.
After incubation with the diabody cells were washed twice with
PBS and treated with DMEM0.1, latent TGFb1 (Cell Signaling
Technology) at 50 ng/ml or TGFb1 (R&D Systems) at 10 ng/ml
for 30 min at 37uC. After extensive washing with PBS, 4%
formaldehyde was used to fix the cells (15 min at 4uC). Cells were
then permeabilized with 0.3% Triton-X 100 (Sigma) in PBS and
cover slips were blocked for 1 h with 5% goat serum before
overnight incubation with rabbit anti-Smad2/3 antibody (Cell
Signaling Technology) at 4uC. The following day, primary
antibody was detected with Alexa Fluor 488H-labeled goat anti-
rabbit IgG (Invitrogen) containing Hoechst trihydrochloride
(Invitrogen). Cover slips were mounted on slides using ProLong
Gold antifade (Invitrogen) and examined using a Zeiss AxioImager
A1 fluorescence microscope with AxioVision software.
In vivo studies
All experiments were conducted with previous approval from
the UK Home Office, under PPL 70/6677. Female SCID mice
were injected subcutaneously (s.c.) with 46106 A375Pb6 cells in
one flank, and 46106 A375Ppuro cells in the contralateral flank, in
150 ml serum-free DMEM. Once tumors reached a diameter of
around 5 mm, approximately 11 mg (30MBq) per mouse of 99mTc-
labeled B6.3 diabody in 200 ml PBS was injected intravenously
(i.v.). Mice were anaesthetised with isoflurane and imaged 2 h, 5 h
and 24 h after injection using a Nano-SPECT/CT scanner
(Bioscan, Washington, DC, USA). SPECT images were analysed
using in vivo Scope software (Bioscan). Mice were sacrificed 24 h
after injection of diabody; tissues were excised and radioactivity
measured on a gamma counter (LKB Compugamma, Victoria,
Australia) alongside standards prepared from the injectate. Uptake
of radioactivity in individual tissues was expressed as a percentage
of the injected radioactive dose per gram (%ID/g).
Results
Expression and characterisation of B6.3 diabody
B6.3 diabody was generated as soluble protein by fermentation
in P. pastoris giving a yield of 175 mg/L. The diabody was purified
from the bioreactor broth using expanded bed IMAC, exploiting
the engineered hexahistidine tag, and concentrated to 2.27 mg/
ml. There was no evidence of aggregation when the product was
tested by size-exclusion chromatography; diabody eluted as a
single peak of .44 kDa, consistent with its calculated MW of
55,322Da (Fig. 1A). The protein was essentially pure as shown by
SDS-PAGE and was revealed as a monomer under denaturating
conditions (Fig. 1A), consistent with diabody formation by non-
covalent association. We next analysed the binding affinity of the
purified B6.3 diabody to avb6. SPR showed that avb6 bound to
B6.3 diabody in a concentration-dependent manner (Fig. 1B) and
subsequently remained associated. Fitting of the data to a
Langmuir 1:1 model gave an affinity constant (KD) value of
2.7821029M and kinetic rate constants of ka
= 8.1610367.3 s21M21 and kd =2.36102561.461027s21.
Interactions with avb6-expressing cells
Specificity of purified B6.3 diabody for avb6 on tumor cells was
assessed by flow cytometry using the avb6-expressing cell line,
A375Pb6, and corresponding avb6-negative A375Ppuro cells. The
Figure 4. Labeling with 99mTc did not affect B6.3 diabody binding to avb6. A) Saturation Binding experiment showed concentration-
dependent binding of 99mTc-labeled diabody to A375Pb6 cells. Non-specific binding, including 25 mg of unlabeled diabody was subtracted from each
data point. KD obtained was 4.8860.3261028 M and BMax was 2.360.0396105 receptors/cell (32565.53 pM/8.56105 cells). B) Scatchard
presentation of the data. Each experiment was carried out in duplicate.
doi:10.1371/journal.pone.0073260.g004
Generation of Diabody Targeting the avb6 Integrin
PLOS ONE | www.plosone.org 5 September 2013 | Volume 8 | Issue 9 | e73260
results showed that B6.3 diabody bound to the avb6-expressing
cells in a concentration-dependent manner (Fig. 1C) but did not
bind to the avb6-negative cells when tested at the two highest
concentrations (Fig. 1C). The shift in fluorescence intensity
observed for binding to A375Pb6 cells were similar at 22.6, 45.1
and 90.2 nM, indicating that antigen saturation was reached at
these concentrations. To further verify the specificity of the B6.3
diabody to avb6, cells were pre-incubated with an anti-avb6
Figure 5. 99mTc-labeled B6.3 diabody localised specifically to avb6-expressing tumors in vivo. A) A375Pb6 and A375Ppuro cells were
injected subcutaneously on opposite shoulders and 99mTc-labeled B6.3 diabody (approximately 11 mg, 30 MBq) was injected intravenously once
tumours had developed. Mice were imaged by SPECT/CT as indicated 2 h, 5 h and 24 h after injection. B) SPECT/CT cross sections of the same mice at
2, 5 and 24 h. C) Percent injected doses of 99mTc-labeled B6.3 diabody in A375Pb6 and A375Ppuro tumours from three mice, obtained from these
images. D) Biodistribution of 99mTc-labeled B6.3 diabody 24 h after injection. Data expressed as % injected dose/g (%ID/g) as mean 6 SD for 5
animals. Tumor-to blood ratios at this time point were 40.4 for A375Pb6 tumors and 15.5 for A375Ppuro tumors. Significance assessed by Student’s t-
test.
doi:10.1371/journal.pone.0073260.g005
Generation of Diabody Targeting the avb6 Integrin
PLOS ONE | www.plosone.org 6 September 2013 | Volume 8 | Issue 9 | e73260
antibody, 10D5. This resulted in inhibition of B6.3 diabody
binding when 10D5 was used at 10 and 100 nM (Fig. 1D).
Next we tested whether the diabody would internalize
specifically into the avb6-expressing cells, as previously reported
for other ligand-mimic antibodies targeting this integrin [27]. Cells
were treated with B6.3 diabody at 4uC for 1 h to allow binding to
the outer cell membrane. Then, temperature was increased to
37uC for different length of time to allow internalization and the
resulting cellular distribution of the diabody was revealed after
fixation and permeabilization by fluorescence staining. Results of
these experiments showed that, upon binding at 4uC, B6.3
diabody was localized at the cell surface (Fig. 2A). When the
temperature was raised to 37uC surface staining disappeared and
the diabody was found inside the cells after 30 min, 1 h and 3 h of
incubation (Fig. 2A).
B6.3 diabody-mediated blockade of avb6 biological
functions
The avb6 integrin is known to have a role in the promotion of
cell migration based on interaction with components of the
extracellular matrix [6,11,16]. Since the B6.3 diabody contained
an RGD motif and internalized as a ligand-mimic antibody, we
investigated whether the diabody would exhibit biological effects
associated with integrin blockade. First we tested the ability of the
diabody to inhibit adhesion and migration of avb6-positive or
negative cells to the avb6 ligands, LAP and fibronectin. In addition
to the stably-transfected A375Pb6 cells, we included the naturally
avb6-expressing pancreatic cancer cell line Capan-1. Treatment
with B6.3 diabody at 50 mg/ml resulted in a reduction in adhesion
of A375Pb6 and Capan-1 cells to LAP-coated plates (Fig. 2B). In
addition, we observed a decrease in the number of Capan-1 cells
attached to fibronectin-coated plates. The shMFE23 diabody
targeting the carcinoembryonic antigen (CEA) was used as control;
pre-treatment with this diabody had no effect on the CEA-positive
Capan-1 cells or the melanoma cell lines, negative for CEA [17].
The results from Transwell migration assays were more marked as
the B6.3 diabody induced an almost complete inhibition of
migration towards LAP in both A375Pb6 and Capan-1 cells
(Fig. 2C). In addition, the migration of Capan-1 cells to fibronectin
was almost completely inhibited by the diabody, indicating that
avb6 is the major fibronectin-binding integrin on Capan-1. In
contrast, B6.3 diabody did not block A375Pb6 cells adhering to or
migrating on fibronectin (Fig 2C), consistent with our previous
data that showed both A375Pb6 and A375Ppuro express two
other fibronectin-binding integrins avb3 and a5b1 [17]. No effect
on adhesion or migration was observed in the avb6-negative cell
line A375Ppuro or after addition of an irrelevant diabody,
indicating that the B6.3-dependent inhibition was avb6-specific.
The avb6 integrin is known to activate TGFb1 upon interaction
with its latent form (LAP-TGFb1 complex), resulting in TGFb-
induced smad2/3 phosphorylation and subsequent translocation
of smad2/3 to the nucleus [7]. We hypothesized that binding of
B6.3 diabody to avb6 would inhibit its interaction with latent
TGFb1 and downstream Smad2/3 translocation. We showed that
smad2/3 localized in the cytoplasm in serum-starved Capan-1
cells (Fig. 3(a)). Incubation with B6.3 diabody had no effect on
smad2/3 localization (Fig. 3(c)), while treatment with latent
TGFb1 resulted in nuclear translocation of Smad2/3 (Fig. 3(b)).
We next tested the localization of smad2/3 after incubation with
the B6.3 diabody. Our data showed that B6.3 diabody inhibited
Smad2/3 nuclear translocation mediated by latent TGFb1
(Fig. 3(d)), indicating that the diabody blocked smad2/3 activation.
Active TGFb1 showed Smad2/3 translocation in B6.3-treated cells
(Fig. 3(f)), since the active form does not require prior integrin
interactions.
Labeling efficiency of B6.3 diabody
In order to determine the efficacy of the diabody for avb6
targeting in vivo, B6.3 diabody was labeled with 99mTc. This
radionuclide was chosen as it has been described previously to be
appropriate for use with internalizing antibody fragments [28] and
the chemistry for conjugation to the hexahistidine tag is
commercially available using the IsoLinkTm kit. After labelling,
the resulting 99mTc-labeled diabody had a specific activity of
2.7MBq/mg and remained a dimer when tested by size-exclusion
chromatography (data not shown). Strength and specificity of
interaction of 99mTc-labeled diabody with purified avb6 protein
was evaluated using a saturation binding experiment which
revealed a concentration-dependent increase of 99mTc-B6.3 dia-
body (Fig. 4A). The specificity of interaction was tested by
inhibition of binding by unlabeled diabody. The non-specific
binding obtained from the inhibition experiments was subtracted
from the total radioactivity to obtain specific binding. When tested
on cells, the affinity constant derived from non-linear regression
analysis of 99mTc-labeled B6.3 diabody was found to be in the
nanomolar range, at 4.8860.3261028 M. The maximal number
of avb6 binding sites (Bmax) was derived to be 2.360.039610
5 per
cell. The Scatchard analysis, which showed a linear correlation
(Fig. 4B), was in agreement with a single affinity binding site for
the interaction.
Targeting of B6.3 diabody to avb6-expressing tumors in
vivo
To determine the specificity of the B6.3 diabody in vivo, 99mTc-
labeled diabody was administered to SCID mice bearing flanking
tumors of A375Pb6 and A375Ppuro cells. Localization of labeled
diabody was monitored by whole body cross-section imaging using
NanoSPECT/CT. Results of these experiments showed that the
avb6-expressing A375Pb6 tumor was detected with the radio-
labeled diabody 2h after injection and remained detectable after
5 h and 24 h (Fig. 5A, 5B). Quantification revealed significantly
more radioactivity in the avb6-expressing tumors when compared
to the A375Ppuro tumors at all three time points; the uptake was
highest 5 h after injection and considerably reduced after 24 h but
remained still clearly detectable (Fig. 5C). The highest normal
tissue activity was found in the kidneys, a typical pattern found for
radio-metal-labeled compounds due to the excretion of 99mTc-
labeled compound by this organ.
Twenty-four hours after injection and imaging, the mice were
sacrificed and biodistribution of 99mTc-labeled diabody was
determined (Fig. 5D). The data showed that %ID/g obtained in
A375Pb6 tumors was significantly higher (p,0.0005) than that in
the A375Ppuro tumors, in agreement with quantification from
imaging at this time point. Tumor-to-Blood ratios of 40 were
obtained for the avb6 positive tumor whereas the avb6 negative
tumor gave a ratio of 15.5. The kidney had the highest %ID/g of
any organ in agreement with the imaging results. Imaging and
biodistribution studies showed that 99mTc-labeled diabody targets
specifically to avb6-expressing tumors in vivo and is detectable 24 h
after injection with tumor-to-blood ratios suitable for imaging.
Discussion
This work describes the generation and characterization of a
novel diabody that specifically targets the avb6 integrin. The
diabody was produced as a soluble secreted protein in P. pastoris,
allowing rapid production using a process readily adaptable to
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manufacture of clinical grade material [24,25]. The engineered
hexahistidine tag allowed purification and successful labeling with
99mTc, without affecting the nanomolar binding affinity of the
diabody on cells in vitro.
Our studies also showed that the diabody inhibited adhesion
and migration of the avb6-transfected melanoma cell line,
A375Pb6 and the pancreatic adenocarcinoma cell line, Capan-1,
to LAP. This is the desired function-blocking activity of anti-avb6
and has been observed with whole anti-avb6 antibodies that block
in vitro migration of avb6–positive Detroit 562 human pharyngeal
carcinoma cells and inhibit tumor growth in vivo by suppressing
TGFb activation [16,27]. When interactions via fibronectin, a less
specific ligand, were investigated, the diabody was found to inhibit
adhesion and migration of Capan-1 cells but not A375Pb6 cells.
This highlights the specificity of B6.3 because A375Pb6 cells
express other fibronectin-binding integrins [17] that would not be
blocked by an avb6-specific agent. The avb6 integrin activates
latent-TGFb first by binding to LAP and then through cortical
actin-dependent mechanical forces that causes distortion of the
LAP molecule, releasing the TGFb [29,30]. Targeting avb6 with
the B6.3 diabody inhibited this interaction with LAP, resulting in
inhibition of Smad2/3 translocation to the nucleus.
The role of avb6-dependent TGFb activation in cancer has been
investigated in a number of studies [31,32,33,34,35], that illustrate
both the potential and complexity associated with this target. For
example, when avb6 was blocked with antibodies in the early
stages of disease in a transgenic pancreatic cancer mouse model,
this accelerated cancer progression when SMAD4 was functional,
but not in SMAD4-null animals [34]. In separate studies avb6
promoted cancer growth and liver metastasis through activation of
TGFb [11,36]. Thus, the functional blockade of avb6 has positive
therapeutic implications due to the potential inhibition of TGFb,
although TGFb can also act as a tumour suppressor in normal
epithelium and pre-malignant transformed epithelial cells. How-
ever, cancer cells often develop mutations that prevent TGFb-
mediated growth inhibition, making TGFb a strong tumor
promoter [32,33]. Therefore therapeutic antibody blockade of
avb6 can suppress tumour growth [16,35] but the molecular
phenotype of the tumor must be taken into consideration.
When tested for avb6 localization in vivo, the radiolabeled
diabody showed specific targeting of avb6-positive tumours,
detectable as early as two hours after injection. Signal was
measurable over 24 hours, although intensity was highest five
hours after injection. Radiolabeling with 99mTc, using site-specific
attachment to the engineered hexahistidine tag, was found to be
simple and efficient. Furthermore, use of 99mTc allowed
residualization of the signal within the tumor upon internalization
of the diabody. These characteristics, combined with the ease of
production of B6.3 and its favourable biodistribution in vivo, make
this diabody an attractive tool for clinical imaging.
The diabody format has not yet been fully exploited as a cancer
targeting agent, but it has many attractive features. The bivalency
of diabodies conferred by their dimeric structure holds the
advantage of higher tumor uptake compared to scFv fragments,
resulting in higher signals when used as imaging agents [37]. Also
the bigger size of diabodies in relation to scFv increases their
circulatory half life, resulting in higher accumulation in the tumor,
while achieving better contrast at short time points than bigger
engineered fragments such as minibodies [38]. However, despite
higher contrast and early imaging, radiometal-labeling of
diabodies also results in considerable kidney retention, as shown
in our current study and by other groups [22,37,38]. This can be
problematic if imaging is desirable in close areas. Attachment of
polyethylene glycol (PEG) to diabodies has shown to significantly
lower kidney retention [22] and improvement of pharmacokinetics
[21], resulting in increased circulating time that did not affect the
collection of optimal images within 24 hours. The increased
circulating time could in fact be advantageous if diabodies are to
be used for therapeutic purposes, which required maximum tumor
accumulation. In this sense, the internalization of the B6.3 could
be clinically useful for delivery of toxic compounds such as the
radioisotope, conjugated toxic agents should or small toxic drugs,
such as pyrrolobenzodiazepines (PBDs), that are active within
target cells.
In summary, the B6.3 diabody described in our study bound
specifically to avb6 in vitro and targeted specifically to avb6-
expressing tumors in vivo. In addition, the diabody retained the
biological properties of ligand-mimicking antibodies; it showed
internalization upon binding to avb6, successfully blocked avb6-
dependent adhesion and migration to LAP and fibronectin and
inhibited smad2/3 nuclear translocation upon treatment with
latent TGFb1. Based on its function-blocking activity and specific
targeting to avb6-positive cells in vivo, the B6.3 diabody has
potential as an imaging agent or a building block for generation of
therapeutics by chemical coupling of small cytotoxic molecules or
addition of toxic agents.
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